Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma

Tatenda Mahlokozera, Ananth K. Vellimana, Tiandao Li, Diane D. Mao, Zohny S. Zohny, David H. Kim, David D. Tran, Daniel S. Marcus, Sarah J. Fouke, Jian L. Campian, Gavin P. Dunn, Christopher A. Miller, Albert H. Kim

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background Diagnostic workflows for glioblastoma (GBM) patients increasingly include DNA sequencing-based analysis of a single tumor site following biopsy or resection. We hypothesized that sequencing of multiple sectors within a given tumor would provide a more comprehensive representation of the molecular landscape and potentially inform therapeutic strategies. Methods Ten newly diagnosed, isocitrate dehydrogenase 1 (IDH1) wildtype GBM tumor samples were obtained from 2 (n = 9) or 4 (n = 1) spatially distinct tumor regions. Tumor and matched blood DNA samples underwent whole-exome sequencing. Results Across all 10 tumors, 51% of mutations were clonal and 3% were subclonal and shared in different sectors, whereas 46% of mutations were subclonal and private. Two of the 10 tumors exhibited a regional hypermutator state despite being treatment naïve, and remarkably, the high mutational load was predominantly limited to one sector in each tumor. Among the canonical cancer-associated genes, only telomerase reverse transcriptase (TERT) promoter mutations were observed in the founding clone in all tumors. Reconstruction of the clonal architecture in different sectors revealed regionally divergent evolution, and integration of data from 2 sectors increased the resolution of inferred clonal architecture in a given tumor. Predicted therapeutic mutations differed in presence and frequency between tumor regions. Similarly, different sectors exhibited significant divergence in the predicted neoantigen landscape. Conclusions The substantial spatial heterogeneity observed in different GBM tumor sectors, especially in spatially restricted hypermutator cases, raises important caveats to our current dependence on single-sector molecular information to guide either targeted or immune-based treatments.

Original languageEnglish
Pages (from-to)472-483
Number of pages12
JournalNeuro-oncology
Volume20
Issue number4
DOIs
StatePublished - Mar 27 2018

Keywords

  • glioblastoma
  • hypermutator
  • sequencing
  • spatial heterogeneity
  • tumor heterogeneity

Fingerprint Dive into the research topics of 'Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma'. Together they form a unique fingerprint.

  • Cite this